| ID | 60802 |
| JaLCDOI | |
| FullText URL | |
| Author |
Hirabae, Atsuko
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ichihara, Eiki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Kaken ID
publons
Sunami, Ryota
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Ota, Moeko
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Iwamoto, Yoshitaka
Department of Allergy and Respiratory Medicine, Okayama University Hospital
Maeda, Yoshinobu
Department of Hematology, Oncology and Respiratory Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
Kaken ID
researchmap
Kiura, Katsuyuki
Department of Allergy and Respiratory Medicine, Okayama University Hospital
ORCID
Kaken ID
publons
researchmap
|
| Abstract | We report a case of late-onset hyperprogressive disease after cessation of a PD-1 inhibitor. A male was diagnosed with metastatic lung adenocarcinoma with little progression for 2 months before treatment. He received pembrolizumab as a second-line treatment and was subsequently prescribed docetaxel for 3 months until a slight increase in pleural effusion. At the time of progression to docetaxel, he commenced prednisolone because of immune-system-related diarrhea. After that, his general condition rapidly worsened with severe fatigue and hypoxia. Computed tomography revealed a massive increase of pleural effusion and replacement of almost the entire liver with cancer over a period of 5 weeks.
|
| Keywords | lung cancer
immune checkpoint inhibitors
pembrolizumab
hyperprogression
|
| Amo Type | Case Report
|
| Published Date | 2020-10
|
| Publication Title |
Acta Medica Okayama
|
| Volume | volume74
|
| Issue | issue5
|
| Publisher | Okayama University Medical School
|
| Start Page | 423
|
| End Page | 425
|
| ISSN | 0386-300X
|
| NCID | AA00508441
|
| Content Type |
Journal Article
|
| language |
英語
|
| Copyright Holders | CopyrightⒸ 2020 by Okayama University Medical School
|
| File Version | publisher
|
| Refereed |
True
|
| PubMed ID | |
| Web of Science KeyUT | |
| NAID | |
| reference | Champiat S, Dercle L, Ammari S, Massard C, Hollebecque A, Postel-Vinay S, Chaput N, Eggermont A, Marabelle A, Soria JC and Ferté C: Hyperprogressive Disease Is a New Pattern of Progression in Cancer Patients Treated by Anti-PD-1/PD-L1. Clin Cancer Res (2017) 23: 1920-1928.
Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B and Caramella C: Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. JAMA Oncol (2018) 4: 1543-1552.
Kato S, Goodman A, Walavalkar V, Barkauskas DA, Sharabi A and Kurzrock R: Hyperprogressors after Immunotherapy: Analysis of Genomic Alterations Associated with Accelerated Growth Rate. Clin Cancer Res (2017) 23: 4242-4250.
Frelaut M, Le Tourneau C and Borcoman E: Hyperpression under Immunotherapy. Int J Mol Sci (2019) 20: pii: E2674.
Osa A, Uenami T, Koyama S, Fujimoto K, Okuzaki D, Takimoto T, Hirata H, Yano Y, Yokota S, Kinehara Y, Naito Y, Otsuka T, Kanazu M, Kuroyama M, Hamaguchi M, Koba T, Futami Y, Ishijima M, Suga Y, Akazawa Y, Machiyama H, Iwahori K, Takamatsu H, Nagatomo I, Takeda Y, Kida H, Akbay EA, Hammerman PS, Wong KK, Dranoff G, Mori M, Kijima T and Kumanogoh A: Clinical implications of monitoring nivolumab immunokinetics in non-small cell lung cancer patients. JCI Insight (2018) 3: pii: 59125.
Champiat S, Ferrara R, Massard C, Besse B, Marabelle A, Soria JC and Ferté C: Hyperprogressive disease: recognizing a novel pattern to improve patient management. Nat Rev Clin Oncol (2018) 15: 748-762.
|
